Skip to content

Study · Animal study (in vivo) · beagle dog and rat · 2022

6 results

Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.

He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, Zhang W, Wang S, Wang Z, Hao Q, Zhang C, Gao Y and 4 more

Show all authors

Gu J, Zhang Y, Li W, Li M

Frontiers in pharmacology14 Dec 2022Cited by 20 (Europe PMC)

PMID36588717 (opens in a new tab)PMCIDPMC9794587 (opens in a new tab)DOI10.3389/fphar.2022.1026182 (opens in a new tab)PepBankPUB-36588717
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

Body-protective compound (BPC) 157 demonstrates protective effects against damage to various organs and tissues. For future clinical applications, we had previously established a solid-phase synthesis process for BPC157, verified its biological activity in different wound models, and completed preclinical safety evaluations. This study aimed to investigate the pharmacokinetics, excretion, metabolism, and distribution profiles of BPC157. After a single intravenous (IV) administration, single intramuscular (IM) administrations at three doses in successive increments along with repeated IM administrations, the elimination half-life (t1/2) of prototype BPC157 was less than 30 min, and BPC157 showed linear pharmacokinetic characteristics in rats and beagle dogs at all doses. The mean absolute bioavailability of BPC157 following IM injection was approximately 14%-19% in rats and 45%-51% in beagle dogs. Using [3H]-labeled BPC157 and radioactivity examination, we proved that the main excretory pathways of BPC157 involved urine and bile. [3H]BPC157 was rapidly metabolized into a variety of small peptide fragments in vivo, thus forming single amino acids that entered normal amino acid metabolism and excretion pathways. In conclusion, this study provides the first analysis of the pharmacokinetics of BPC157, which will be helpful for its translation in the clinic.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In rats and beagle dogs, the elimination half-life of prototype BPC157 was less than 30 min after IV and IM administration.

    In plain wordsIn rats and dogs, BPC157 was cleared from the blood quickly, with a half-life under 30 minutes.

    Peptide
    BPC-157
    Outcome
    Not applicableElimination half-life of prototype BPC157
    Study

    rat and beagle dogn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenous and intramuscularAs given in this study (rat and beagle dog).

    Measurements

    Elimination half-life
    < 30 min
    prototype BPC157, rats and beagle dogs

    Source sentences

    Summary
    the elimination half-life (t1/2) of prototype BPC157 was less than 30 min
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In rats and beagle dogs, BPC157 showed linear pharmacokinetic characteristics at all doses.

    In plain wordsIn rats and dogs, blood levels of BPC157 rose in proportion to the dose.

    Peptide
    BPC-157
    Outcome
    Not applicableDose linearity of BPC157 pharmacokinetics
    Study

    rat and beagle dogn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenous and intramuscularAs given in this study (rat and beagle dog).

    Source sentences

    Summary
    BPC157 showed linear pharmacokinetic characteristics in rats and beagle dogs at all doses.
  3. 03AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, the mean absolute bioavailability of BPC157 after IM injection was approximately 14%-19%.

    In plain wordsIn rats, about 14 to 19 percent of an intramuscular BPC157 dose reached the blood.

    Peptide
    BPC-157
    Outcome
    Not applicableAbsolute bioavailability after IM injection in rats
    Study

    ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intramuscularAs given in this study (rat).

    Measurements

    Absolute bioavailability
    14 to 19%
    rats, IM

    Source sentences

    Summary
    The mean absolute bioavailability of BPC157 following IM injection was approximately 14%-19% in rats and 45%-51% in beagle dogs.
  4. 04AnimalAnimal study (in vivo)Pharmacokinetics

    In beagle dogs, the mean absolute bioavailability of BPC157 after IM injection was approximately 45%-51%.

    In plain wordsIn dogs, about 45 to 51 percent of an intramuscular BPC157 dose reached the blood.

    Peptide
    BPC-157
    Outcome
    Not applicableAbsolute bioavailability after IM injection in beagle dogs
    Study

    beagle dogn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intramuscularAs given in this study (beagle dog).

    Measurements

    Absolute bioavailability
    45 to 51%
    beagle dogs, IM

    Source sentences

    Summary
    The mean absolute bioavailability of BPC157 following IM injection was approximately 14%-19% in rats and 45%-51% in beagle dogs.
  5. 05AnimalAnimal study (in vivo)Pharmacokinetics

    With [3H]-labeled BPC157, the main excretory pathways involved urine and bile.

    In plain wordsTests with labelled BPC157 showed that the body removes it mainly through urine and bile.

    Peptide
    BPC-157
    Outcome
    Not applicableExcretion pathways of BPC157
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Using [3H]-labeled BPC157 and radioactivity examination, we proved that the main excretory pathways of BPC157 involved urine and bile.
  6. 06AnimalAnimal study (in vivo)Pharmacokinetics

    [3H]BPC157 was rapidly metabolized in vivo into small peptide fragments and single amino acids that entered normal amino acid metabolism and excretion pathways.

    In plain wordsThe body quickly broke labelled BPC157 into small fragments and single amino acids that enter normal amino acid pathways.

    Peptide
    BPC-157
    Outcome
    Not applicableMetabolism of BPC157 in vivo
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    [3H]BPC157 was rapidly metabolized into a variety of small peptide fragments in vivo, thus forming single amino acids that entered normal amino acid metabolism and excretion pathways.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.